|1.||Fontana, Karina: 2 articles (01/2010 - 10/2008)|
|2.||Kölle, Markus A: 1 article (10/2012)|
|3.||Freudenmann, Roland W: 1 article (10/2012)|
|4.||Baumgarten, Eik: 1 article (10/2012)|
|5.||Gahr, Maximilian: 1 article (10/2012)|
|6.||Rastrelli, Giulia: 1 article (06/2012)|
|7.||Vignozzi, Linda: 1 article (06/2012)|
|8.||Corona, Giovanni: 1 article (06/2012)|
|9.||Maggi, Mario: 1 article (06/2012)|
|10.||Allouh, Mohammed Z: 1 article (05/2012)|
07/01/1987 - "Mesterolone was found to be effective in improving the sperm concentration in mild and moderate rather than in severe idiopathic oligospermia."
02/01/1988 - "Mesterolone was found to be more useful in patients with a sperm count ranging between 5 and 20 million/ml. Those with severe oligospermia (count less than 5 million) do not seem to benefit from this therapy."
02/01/1988 - "Two hundred fifty subfertile men with idiopathic oligospermia (count less than 20 million/ml) were treated with mesterolone (100-150 mg/day) for 12 months. "
07/01/1987 - "Forty subfertile men with idiopathic oligospermia were randomly treated with mesterolone or with placebo for more than 4 months. "
07/01/1987 - "The effects of mesterolone on sperm count in idiopathic oligospermia."
|2.||Male Infertility (Male Sterility)
03/01/1991 - "Placebo-controlled trial of high-dose Mesterolone treatment of idiopathic male infertility."
03/01/1991 - "Because similar semen improvement also occurred in the placebo controls, our findings cast doubt on the possible usefulness of high-dose Mesterolone treatment of idiopathic male infertility."
08/01/1989 - "Mesterolone and idiopathic male infertility: a double-blind study. "
04/01/1975 - " It is concluded that mesterolone is a useful addition to the therapeutic arsenal for the treatment of male infertility."
11/01/1973 - "Mesterolone in the treatment of male infertility."
|3.||Hypogonadism (Hypergonadotropic Hypogonadism)
05/01/2012 - "Mesterolone is a synthetic oral anabolic androgenic steroid used to treat hypogonadism. "
01/01/1974 - "[Depot mesterolone therapy in hypogonadism]."
01/01/2003 - "In men with primary hypogonadism, the BMD increased dose dependently (crystalline testosterone +7.0 +/- 1.3%, testosterone enanthate +4.8 +/- 0.2%, testosterone undecanoate +3.4 +/- 2.5%, mesterolone +0.8 +/- 1.6%) after 6 months of therapy. "
07/28/1997 - "In order to investigate differential effects of androgens on erythropoiesis, 55 men with clincally and biochemical confirmed hypogonadism were randomly assigned to 4 groups receiving different forms of androgen substitution: Mesterolone (MES) 100 mg/d, testosterone undecanoate (TU) 160 mg/d, testosterone enanthate (TE) 250 mg i.m./21 days or 1200 mg crystalline testosterone (TPEL) subcutaneously implanted at study begin. "
01/01/1980 - "A clinical and endocrine study of mesterolone in secondary impotence."
01/01/1972 - "A pilot study of mesterolone in impotence."
05/01/2012 - "This study indicates that mesterolone can induce avian skeletal muscle hypertrophy and that this is correlated with increased number of SCs. "
05/01/2012 - "Specifically, this study tested the hypotheses that mesterolone induces avian skeletal muscle hypertrophy, and that mesterolone increases the number of SCs in avian skeletal muscle. "
05/01/2012 - "As SC activation and subsequent differentiation to new myonuclei is a major event during muscle hypertrophy, this study investigated the influence of mesterolone on SC distribution within the pectoralis muscle of chickens. "
05/01/2012 - "We suggest that SCs are key cellular intermediaries for mesterolone-induced muscle hypertrophy."
01/01/2010 - "Muscles from animals that had been both exercised and treated with mesterolone exhibited the largest changes: muscle mass and muscle fibre hypertrophy was greater than in all other groups of animals, capillarity was higher and >30% of all recognized satellite cells exhibited signs of activation. "
|5.||testosterone enanthate (Delatestryl)
|10.||Ascorbic Acid (Vitamin C)